Cancer and Metastasis Reviews

Papers
(The median citation count of Cancer and Metastasis Reviews is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities358
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer226
Obesity and cancer221
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms142
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions140
The functions and modifications of tRNA-derived small RNAs in cancer biology118
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression107
Clonal tracking in cancer and metastasis91
Regulation of dormancy during tumor dissemination: the role of the ECM84
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?71
Targeting lipid metabolism in cancer: neuroblastoma69
CAR T-cell therapy to treat multiple myeloma: current state and future directions68
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer61
p73 isoforms meet evolution of metastasis60
Cell-cell interactions mediating primary and metastatic breast cancer dormancy59
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review56
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives47
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?47
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond46
Biography—Mathieu Boissan, Pharm.D., Ph.D45
Preface42
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer40
Neuropeptide Y in cancer—biological functions and potential clinical implications40
Biographies39
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance39
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance37
The role of cancer cell bioenergetics in dormancy and drug resistance36
Short-chain fatty acids in cancer pathogenesis36
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications36
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy36
Tumor necrosis factor superfamily signaling: life and death in cancer35
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy35
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development35
Clusterin: a marker and mediator of chemoresistance in colorectal cancer35
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions34
Clinical interventions to break the obesity and cancer link: a narrative review34
The emerging roles of histone demethylases in cancers33
Vaping and tumor metastasis: current insights and progress33
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy33
Carcinoma of unknown primary (CUP): an update for histopathologists32
Functional and clinical roles of stromal PDGF receptors in tumor biology31
Kenneth V. Honn, Ph.D. (1946–2023)30
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution29
OX40/OX40 ligand and its role in precision immune oncology29
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape29
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy28
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect27
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective27
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases26
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting26
New progress of tuberculosis scar carcinoma26
Ferroptosis: iron release mechanisms in the bioenergetic process25
HOXA9 transcription factor is a double-edged sword: from development to cancer progression25
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases24
Is cancer an intelligent species?24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies24
Biographies24
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics24
The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets23
Metastasis suppressor genes in clinical practice: are they druggable?23
Metastasis suppressor genes and their role in the tumor microenvironment23
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment23
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs23
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets23
The role of bone marrow adipocytes in cancer progression: the impact of obesity22
Role of myeloid-derived suppressor cells in tumor recurrence22
Correction to: The gut microbiome, immune check point inhibition and immune‑related adverse events in non‑small cell lung cancer22
Lost at SCLC: a review of potential platinum sensitizers22
The diversity of natural killer cell functional and phenotypic states in cancer22
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers21
Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy21
Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma21
Preface20
Influence of antibody–drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis20
Biography—Mikhail Kolonin20
Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer20
The role of obesity and bariatric surgery-induced weight loss in breast cancer20
Preface20
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors19
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions19
The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer19
Cancer cell plasticity, stem cell factors, and therapy resistance: how are they linked?19
Potential biomarkers for immunotherapy in non-small-cell lung cancer18
Biographies18
Multiomics approach towards characterization of tumor cell plasticity and its significance in precision and personalized medicine18
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics18
Therapeutic importance and diagnostic function of circRNAs in urological cancers: from metastasis to drug resistance18
Minimally invasive biomarkers for triaging lung nodules—challenges and future perspectives17
Epigenetic drugs in cancer therapy17
Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies17
Epigenetic control of pancreatic cancer metastasis17
The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin17
Insights into the role of senescence in tumor dormancy: mechanisms and applications16
The timing of adiposity and changes in the life course on the risk of cancer16
The roles of periostin derived from cancer-associated fibroblasts in tumor progression and treatment response16
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings16
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response15
Advancements in gene therapies targeting mutant KRAS in cancers15
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance15
Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies15
Epigenetic markers and therapeutic targets for metastasis15
Preface15
Recapitulating the potential contribution of protein S-palmitoylation in cancer15
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance15
Natural compounds targeting nuclear receptors for effective cancer therapy15
Glioblastoma stem cell metabolism and immunity14
Epigenetic changes and the dynamic heterogeneity of the metastatic phenotype – challenges ahead14
Oral delivery of RNAi for cancer therapy14
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance14
Evolving strategies for addressing CAR T-cell toxicities14
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases14
0.2554349899292